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doi:10.1016/j.ejvs.2009.12.008Abstract Purpose: This study aims to evaluate the medium-term outcomes following aortic
aneurysm repair using fenestrated endografts performed in 16 French academic centres.
Materials andmethods: A retrospective analysis of prospectively collected datawas carried out.
This study included all patients treatedwith fenestrated endografts in France betweenMay 2004
and January 2009. Patients were judged to be at high risk for open surgical repair. Fenestrated
endografts were designed using computed tomography (CT) reconstructions performed on
three-dimensional (3D) workstations. All patients were evaluated with CT, duplex ultrasound
and plain film radiograph at discharge, 6, 12, 18 and 24 months, and annually thereafter.
Results: A total of 134 patients (129 males) were treated over the study period. Median age and
aneurysm size were 73 years (range 48e91 years) and 56 mm (range 45e91 mm), respectively. A
total of 403 visceral vessels were perfused through a fabric fenestration, including 265 renal
arteries. One early conversion to open surgery was required. Completion angiography and
discharge CT scan showed that 398/403 (99%) and 389/394 (99%) respective target vessels were
patent. The 30-day mortality rate was 2% (3/134). Pre-discharge imaging identified 16 (12%)
endoleaks: three type I, 12 type II and one type III. After the procedure, transient or permanent
dialysis was required in four (3%) and two (1%) patients, respectively. The median duration of
follow-up was 15 months (range 2e53 months). No aneurysms ruptured or required openjvs.2010.01.004.
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538 S. Amiot et al.conversion during the follow-up period. Twelve of 131 patients (9%) died during follow-up (actu-
arial survival at 12 and 24 months: 93% and 86%, respectively). Median time from procedure to
deathwas 15months. None of these deathswere aneurysm related. Aneurysm sac size decreased
bymore than 5mm in 52%, 65.6% and 75% of patients at 1, 2 and 3 years, respectively. Three (4%)
patients had sac enlargement within the first year, associated with a persistent endoleak. During
follow-up, four renal artery occlusions were detected. A total of 12 procedure-related re-inter-
ventions were performed in 12 patients during follow-up, including six to correct endoleaks, and
five to correct threatened visceral vessels.
Conclusions: The use of endovascular prostheses with graft material incorporating the visceral
arteries is safe and effective in preventing rupture in the medium term. A predictable high
mortality rate was depicted during follow-up in this high-risk cohort. Meticulous follow-up to
assess sac behaviour and visceral ostia is critical to ensure optimal results.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.In prospective randomised trials, endovascular aneurysm
repair (EVAR) proved to have a lower early morbidity and
mortality compared with open repair.1,2 Nevertheless, an
adequate proximal sealing zone is required to seal the
aneurysm using conventional devices.3 Advances in endo-
vascular skills and technology offer the possibility of treating
abdominal aneurysms with short necks (i.e., less than 10 mm
long) or including visceral vessels.4 Depending on the defi-
nition, the proportion of juxtarenal aneurysms (JRAs) ranges
from 2% to 20% of abdominal aortic aneurysms (AAAs).5e7
Some authors opine that there is no exact definition of JRA.8
Others include intra-operative data in their definition of
JRA.9 According to reporting standards, short-neck infrare-
nal AAAs were classified as juxtarenal when extending to
renal arteries without involving them.10 Suprarenal aneu-
rysms involve renal arteries or renal and splanchnic arteries.
Type IV thoraco-abdominal aortic aneurysms extend on
a variable abdominal length, and always involve the visceral
aortic segment.11 Fenestrated devices were designed to
ensure the proximal sealing of these three aneurysm types
and maintain antegrade perfusion of the vessels conse-
quently included in the fabric. The purpose of this study was
to evaluate the medium-term outcomes following aortic
aneurysm repair using fenestrated endografts performed in
16 French academic centres. It is an update of our previous
report evaluating the first 80 patients treated in France with
fenestrated endografts.12
Material and methods
Aneurysms
All consecutive patients treated with fenestrated endog-
rafts in France between May 2004 and January 2009 were
included. The aneurysms treated were juxtarenal, supra-
renal and Crawford type IV thoraco-abdominal aneurysms.
All aneurysms were asymptomatic. No patient had a prior
EVAR. No fenestrated devices were implanted to treat
infected or ruptured aneurysms. A visceral artery stenosis
was considered significant when resulting in a more than
70% diameter reduction.
Co-morbidities
All patients were deemed to be at physiological high risk
for open surgical repair. The high-risk criteria for openAAA repair have been determined by the Agence Fran-
c¸aise de Se´curite´ Sanitaire des Produits de Sante´ (AFS-
SAPS),13 the French counterpart of the US Food and Drug
Administration. Congestive cardiac failure was defined
according to the New York Heart Association (NYHA)
classification. A left ventricle ejection fraction (LVEF) of
less than 40% was considered to be a high-risk criterion.
Active and former smokers were included in the ‘tobacco
use’ criterion. Lower limb atherosclerosis was defined by
abolition of at least one lower limb pulse and/or an
ankleebrachial index lower than 0.9. No patient had
critical lower limb ischaemia. Each patient having
a previous laparotomy, for any reason, was recorded as
having a hostile abdomen. Using the Cockroft and Gault
formula, we took an absolute cutoff at 60 ml mine1 for
the estimated glomerular filtration rate (eGFR) to
consider a patient having chronic renal insufficiency. A
relative decrease and a relative increase were considered
to be significant when respectively greater than 30% and
10%.14 The need for transient or chronic postoperative
haemodialysis was recorded.
Endografts
The platform of the CE-approved fenestrated endograft
manufactured by Cook Inc. (Bloomington, IN, USA) was the
one used in all patients. It is a three-component endograft,
including a proximal tubular fenestrated body component
(FBC), a bifurcated body and an iliac leg extension. The
fenestrations are of three types: small, large and scallops.
The design of these custom-built three-component fabrics
requires high-resolution spiral computed tomography (CT)
scans (0.75 mm reconstructions) and three-dimensional
(3D) workstations. The design and implantation procedures
have previously been described.12 The size of the delivery
system ranges from 20Fr to 24Fr. No ‘homemade’ devices
were used.
Follow-up
Postoperative follow-up included a clinical and radiological
evaluation with CT, renal duplex ultrasound and plain film
radiograph at discharge, 6, 12, 18 and 24 months, and
annually thereafter. A decrease or an increase in maximal
aneurysm diameter was considered as significant when
>5 mm. Serum level of creatinine and corresponding eGFR
Fenestrated Endovascular Grafting 539were recorded. Early results included the period spreading
from the day of procedure itself to the 30th postoperative
day. Late results include the next steps of the follow-up.
Results
Patients
A total of 134 patients (129 men and five women) were
treated. The median age was 73 years (range 48e91
years). The preoperative risk factors, including the high-
risk criteria for open AAA surgery, are listed in Table 1.
Chronic renal insufficiency was diagnosed in 40% of
patients; none of them required chronic haemodialysis
before the procedure. The eGFR was <30 ml mine1 in
11.1% of patients, and <40 ml mine1 in 22.2% of patients. A
unilateral renal artery stenosis was diagnosed in 13
patients (9.7%), and bilateral renal artery stenosis in two
patients (1.5%). Chronic renal insufficiency was found in
eight of those with unilateral stenosis (62%) and in both
patients with bilateral stenosis.
Aneurysms
The aneurysms were juxtarenal (nZ 99, 73.9%), suprarenal
(n Z 27, 20.1%) and type IV thoraco-abdominal aneurysms
(n Z 8, 6%). Median maximum aortic diameter was 56 mm
(range, 45e91 mm). A previous open AAA tube graft repair
had been performed in five patients (3.7%).
Endografts
A three-component system was deployed in 125/134
patients (93.3%). In three patients (2.2%), a tapered aorto-Table 1 Open surgery high-risk criteria and preoperative
co-morbidities.
Patients (n) %
Age > 80 years 12 9
CABG/coronary stent or previous MIa 74 55
Congestive cardiac failureb 24 18
LVEF < 40% 22 16
COPDc 59 44
Chronic renal insufficiency 54 40
Hostile abdomen 49 37
Obesity (BMI > 30) 23 17
Tobacco use 109 81
Lower limb atherosclerosis 27 20
Diabetes 21 16
Hypertension 81 60
Dyslipidemia 59 44
Previous stroke 19 14
a Patients with positive stress test and no possible new
coronary revascularization (or no indication).
b Patients with clinical symptoms of CHF.
c COPD Z PEFR < 1.2 l/s, or VC < 50% of predicted VC
according to age, sex and weight, or baseline PaCO2 > 45 mmHg
or PaO2 < 60 mmHg, or Home oxygen.uni-iliac distal component was implanted because of severe
unilateral iliac atherosclerotic lesions. The five patients
with previous AAA open-tube repair were treated with FBC
alone. A single FBC was used to treat the only saccular
aneurysm.
A total of 403 visceral vessels were incorporated in the
prosthesis design. The median number of target vessels per
patient was 3 (range: 2e5 vessels). Small fenestrations
were used in 243 cases, large fenestrations in 26 cases and
scallop fenestrations in 133 cases. One branch was designed
to perfuse a ‘downward pointing’ coeliac trunk in a patient
with a type IV thoraco-abdominal aortic aneurysm. The
most frequent FBC configuration (64%) associated a scallop
for the small mesenteric artery (SMA) and a small fenes-
tration for each renal artery.
Procedures
The procedures were conducted in 16 French academic
centres. Concomitant beating heart coronary artery bypass
graft was performed in one patient. In two patients with
severe external iliac artery atherosclerosis; a conduit to the
common iliac artery was performed. In a third patient with
unilateral severe iliac atherosclerosis, a specific one-side
delivery system was used.
The median procedure time was 180 min (range
85e720 min), with a median of 40 min of fluoroscopy time
(range 10e230 min). The median volume of contrast used
was 160 ml (range 50e450 ml). The volume of contrast was
more than 200 ml in 24 (18%) patients. Among patients with
a preoperative GFR <40 ml mine1, the median volume of
contrast used was 192 ml (range 65e280 ml).
The procedure was performed under general anaes-
thesia in 129 cases (96.3%), and under loco-regional
anaesthesia in five cases. These five patients had severe
chronic obstructive pulmonary disease (COPD).
Conversion
Conversion to open surgery was required in one patient
(1%). After successful implantation of the FBC component
and of both renal stents, an occlusion of the native aortic
bifurcation was identified. Through a left retroperitoneal
approach, an aortobifemoral bypass graft was anastomosed
to the fenestrated endograft.
Additional procedures
The following non-planned additional procedures were
performed:
- Repair of femoral or external iliac artery rupture
(n Z 6);
- Repair of common femoral artery puncture-site
dissections (short bypass) (n Z 2);
- Stenting of iliac artery kink (n Z 3) or dissection
(n Z 2);
- Giant Palmaz implantation to treat a proximal type I
endoleak (n Z 1);
- Femoro-popliteal embolectomy (n Z 1);
540 S. Amiot et al.- Implantation of an additional renal stent for renal stent
occlusion (nZ 1), renal stent migration (nZ 1), type III
endoleak (nZ 1) and renal artery rupture (nZ 1); and
- Implantation of an aortic extension to cover a coeliac
trunk (n Z 1).Completion angiography
Completion angiography showed that 398/403 (99%) target
vessels were patent.
The occlusion of four renal arteries and one coeliac
trunk resulted from:
- Distal implantation of a covered renal stent occluding
all renal branches;
- Erroneous implantation of a renal stent in an accessory
polar renal artery instead of the main renal trunk;
- Failed catheterisation of a tight renal ostial stenosis
(n Z 2); and
- Failed catheterisation of a coeliac trunk with tight
stenosis resulting from compression by a median
arcuate ligament.
Another renal artery was not catheterised at the time of
the initial procedure in a patient with a suprarenal aneu-
rysm. This renal artery remained perfused by a type III
endoleak through the small fenestration. A secondary
procedure was successfully performed a few weeks later
(implantation of a covered stent perfusing this renal artery
and occluding the type III endoleak).Table 2 Postoperative non-renal morbidity.
Patient Cardiac and haemodynamic
complications
Vascular
complications
Ne
com
1
2
3 Cardiac arrest
4 Str
rec
5 Cardiac insufficiency
6 Str
rec
7 Cardiac insufficiency
8 Myocardial infarction
9 Cardiac insufficiency
10 Par
11 Myocardial infarction
12 Cardiac insufficiency Tra
att
13
14
15 Atrial fibrillation
16 Myocardial infarction Iliac artery occlusionEarly follow-up
The median length of stay in intensive care unit was 1 day
(range 0e30 days). The median length of stay in hospital
was 9 days (range 4e30 days). The 30-day mortality rate
was 2% (3/134). Two patients died at days 4 and 5,
respectively, after the initial procedure. Both ultimately
died of multisystem organ failure, respectively, after major
perioperative bleeding due to an external iliac artery
rupture and after conversion to open surgery for acute
aortic bifurcation occlusion. The third patient died from
pulmonary oedema, at postoperative day 17. This patient
had a history of coronary artery disease, with a preopera-
tive LVEF estimated at 25%. He had been discharged at
postoperative day 10, after an uneventful postoperative
course.
Morbidity
The non-renal postoperative complications are reported in
Table 2. The external iliac artery occlusion was asymptom-
atic. A negative laparotomywas performed the day following
the procedure for suspected acute mesenteric ischaemia.
A total of 22 complications were noted in 16 patients (12%).
All of the non-renal early postoperative complications were
successfully treated, except the paraparesis, which proved
permanent. A magnetic resonance imaging (MRI) performed
after the procedure demonstrated distal spinal cord
ischaemia in this latter patient. A possible aetiology was the
exclusion of large intercostals by the endograft. Regarding
the two patients who suffered a stroke, MRI demonstratedurological
plications
Respiratory
complications
Digestive
complications
Respiratory
insufficiency
Acute cholecystitis
Suspicion of acute
mesenteric ischaemia
Acute Respiratory
Distress Syndrome
oke, fully
overed
Respiratory
insufficiency
oke, fully
overed
aparesis
nsient ischaemic
ack
Pneumonia
Pneumonia
Respiratory
insufficiency
Table 3 Postoperative renal function (eGFR).
Decrease
N (%)
Increase
N (%)
Stable
N (%)
Temporary dialysis
N (%)
Permanent dialysis
N (%)
Preoperative renal insufficiency
(eGFR < 60 ml/min)
(n Z 53, 40% of patients)
8 (15) 14 (26) 32 (59) 3 (5.5) 1 (2)
Normal preoperative renal
function (eGFR> 60 ml/min)
(n Z 81, 60% of patients)
5 (6) 10 (12) 66 (82) 1 (1) 1 (1)
All 13 (10) 24 (17) 98 (73) 4 (3) 2 (1.5)
Figure 1 KaplaneMeier cumulative survival probability.
Fenestrated Endovascular Grafting 541a right parietal cortical and infracortical infarct in one and
a left capsularethalamic infarct in the other patient.
Neither of these patients had atherosclerotic disease of the
arch. The aetiology remained unclear in both patients.
Renal function
Postoperative evolution of eGFR is reported in Table 3. Renal
function showed a significant improvement or remained
stable among 90% of the patients. After the procedure,
a transient or permanent dialysis was required in four (3%)
and two (1%) patients, respectively. Transient haemodialysis
was required for the two patients with amultisystemic organ
failure, the third patient had preoperative chronic renal
insufficiency and the last one suffered from acute renal
failure associated with cardiac and respiratory insufficiency.
Permanent dialysis was required for a patient who had
preoperative renal insufficiency and patent renal arteries
after the procedure. This renal deterioration probably
resulted from cholesterol emboli. The second case resulted
from a perioperative renal artery thrombosis after failed
catheterisation of this target vessel.
Secondary procedures
Additional four secondary procedures (3%) were performed
in the early postoperative period for repair of two pseudo-
aneurysms (a brachial and a femoral), debridement of
a groin wound and evacuation of a retroperitoneal hae-
matoma in a patient with an iliac conduit.
Discharge CT
Before discharge, a CT was performed in all 131 patients.
A total of 394 remaining target vessels were evaluated. The
target vessels patency rate was 99% (389/394).
An endoleak was diagnosed in 16 (12%) patients: three
type I (two proximal, one distal), 12 type II and one type III.
A proximal type I endoleak was persistent despite implan-
tation of a Palmaz stent in the immediate infrarenal
segment. This endoleak spontaneously sealed on a CT
performed 3 months later. The second proximal type I
endoleak was considered very limited and no immediate
treatment was performed. In the 6 months’ control CT
scan, the aneurysm diameter was unchanged and the
endoleak had resolved. The distal type I endoleak was
successfully treated by implantation of a Palmaz stent on
the distal segment of the left leg. The type III endoleakarose from a renal fenestration that was not catheterised
during the procedure. It was treated by the implantation of
a covered renal artery stent 4 months later.
Late results
Follow-up
The median duration of follow-up was 15 months (range
2e53 months). No patient was lost during follow-up. No
patient developed renal failure requiring dialysis during
follow-up.
Mortality
During follow-up 12 patients died. The cumulative survival
probability according to KaplaneMeier analysis at 12 and 24
months were 93% and 86%, respectively (Fig. 1). The median
time from procedure to death was 15 months. The median
age of patients at the time of death was 75 years (range 62e
91 years). None of these deaths was related to aneurysm.
Carcinoma was the most frequent aetiology, affecting 5 of
these 12 (42%) patients. Myocardial infarction affected three
(25%) patients and the aetiology of one (8%) death remained
Table 4 Secondary interventions during follow-up.
Complication diagnosed Secondary intervention (n) Delay from FEVAR (months)
Type IA endoleak Chimney SMA covered stent þ aortic cuff (1) 18
Type IB endoleak Palmaz stent implantation (1) 2
Type II endoleak Embolisation (2) 3 and 6
Type III endoleak Covered renal stent (1) 4
Type III endoleak Aortic cuff (1) 12
Renal stent fracture Renal artery stenting (4) 6, 12, 18 and 18
Renal stent fracture Hepato-renal bypass (1) 12
Ilio-femoral bypass proximal stenosis Angioplasty (1) 6
Table 5 Endoleaks diagnosed on CT scan during
follow-up.
Follow-up (months) 6 12 18 24 30 36
Number of patients 97 74 45 31 29 19
Type I, n (%) 0 0 1 (2) 0 0 0
Type II, n (%) 13 (13) 6 (8) 2 (4) 1 (3) 0 0
Type III, n (%) 0 1 (1) 0 0 0 0
542 S. Amiot et al.unclear. This patient was suffering from coronary artery
disease and had not shown any specific symptoms. He died 14
months after the procedure, and the last CT performed at 2
months demonstrated complete aneurysm exclusion, with
patent target vessels and stable diameter aneurysm.
Re-interventions
No aneurysms ruptured or required open conversion during
the follow-up period. A total of 12 procedure-related re-
interventions were performed in 12 patients during follow-
up, six to correct endoleaks, five to correct threatened
visceral vessels and one to correct an ilio-femoral bypass,
which had been performed to treat a per procedure
external iliac artery rupture (Table 4):
- Type 2 endoleak embolisation (n Z 2)
- Limb extension to treat a primary distal type I endoleak
- Covered renal stent implanted through a renal fenes-
tration to treat a primary type III endoleak through an
unstented renal fenestration
- Implantation of an aortic cuff to exclude a secondary
type III endoleak
- Chimney technique with a covered stent in the SMA to
treat a secondary proximal type I endoleak
- Complementary renal stenting in the setting of a renal
stent fracture (n Z 4)
- Hepato-renal bypass to treat a renal artery stenosis
- Stenting of a stenosis of a proximal anastomosis of an
ilio-femoral bypass
During follow-up, five non-procedure-related re-inter-
ventions were performed in three patients:
- Recanalisation of superficial femoral artery (n Z 2);
- Implantation of covered stent to exclude a false aneu-
rysm of a previous aortobi-iliac bypass graft (nZ 2); and
- Femoro-popliteal venous bypass and bipolar ligation to
treat a symptomatic popliteal aneurysm.
Median delay for re-interventions was 10 months after
the initial procedure (range, 2e30 months).
Aneurysm diameter
At each follow-up, the difference between the new and the
initial aneurysm diameter was calculated. A significant
aneurysm diameter decrease was depicted in 52%, 65.6%and 75% of patients at 1, 2 and 3 years, respectively. At 6
months, two (2%) patients had a significant increase in
maximal aneurysm diameter, one of them without endo-
leak, and the other with a type II endoleak. This latter
patient remained stable 6 months later. At 1 year of follow-
up, three (4%) patients had sac enlargement, all associated
with a persistent type II endoleak. No treatment was per-
formed, and 6 months later, the three diameters had
remained stable and the three endoleaks persisted. At 18
months, one (2.2%) patient had a sac enlargement. It was
associated with a secondary type I endoleak that was
treated by the chimney technique.
Endoleaks
During follow-up, 15 type II endoleaks (eight primary and
seven secondary) were diagnosed (Table 5). Secondary type
II endoleaks were diagnosed in seven cases, at 6 months
(n Z 3), 1 year (n Z 2), 18 months (n Z 1) and 2 years
(nZ 1). One of them, depicted at 6 months, was associated
with a 5-mm increase in aneurysm diameter. It remained
stable 6 months later. The other four endoleaks were not
associated with a significant increase in maximal aneurysm
diameter.
An increase in maximal aneurysm diameter was observed
in the only patient with a secondary type I endoleak. This
endoleak was treated by the chimney technique, with
implantation of a proximal aortic cuff through a femoral
approach and of a covered SMA stent through a brachial
approach. A major reduction of the endoleak was diagnosed
on the postoperative CT, and no further intervention was
decided for this frail patient.
A secondary type III endoleak was diagnosed in one
patient. This endoleak was perfused by a renal fenestra-
tion that had not been stented due to a failed catheter-
isation of a tight ostial renal stenosis. It was successfully
treated by the implantation of an aortic cuff within the
original FBC.
Fenestrated Endovascular Grafting 543Target vessels patency
During follow-up, four renal artery occlusions were diag-
nosed (3%). One of each was found respectively at 6, 12, 24
and 36 months after the procedure (Table 6). A renal stent
fracture in two cases and preoperative renal artery stenosis
in the other two cases may explain these occlusions. One of
these patients had a renal artery stenosis on the contra-
lateral side to a renal artery occlusion that was treated by
hepato-renal bypass. No coeliac trunk or SMA stenosis or
occlusions were diagnosed during follow-up.Discussion
The first EVAR was described by Parodi in 1991,15 and the
first use of a fenestrated device 8 years later by Far-
uqi.16Fenestrated endografts were initially designed to
treat type I endoleaks complicating standard EVAR,16 and
mycotic aortic aneurysms.17 The possibility of EVAR with
a sealing zone including one or more visceral vessels
allowed the treatment of complex aneurysms. Case reports
were first published, and were followed by single-centre
series. Australian,18 Dutch,19,20 American4,14,21 and
French12 experiences have been published between 2004
and 2009. A decade after its introduction, fenestrated EVAR
is an established technique: more than 2000 patients have
been treated worldwide with fenestrated endovascular
devices, by more than 150 physicians. The population of
endovascular therapists using these custom-made endog-
rafts is following an exponential growth curve. We per-
formed this nationwide multicentre trial to evaluate the
results of fenestrated EVAR performed both within and
outside of referral centres.
Series from referral centres have included between 38
and 119 patients, with 87e302 target vessels. A systematic
review of 19 studies, totalling 715 target vessels, was
published in 2006.22 The 30-day mortality rates following
fenestrated EVAR ranged from 0.84% to 3.4%. A more recent
literature review has pooled eight studies, reporting a total
of 368 patients, all treated with the Zenith fenestrated
endograft.8 In this review, a cumulative mortality following
fenestrated EVAR of 5/368 (1.4%, 95% confidence interval
(CI) 0.4e3.1) is reported. We report in this current study
a 2% early mortality rate. A predictably high mortality rate
was observed during follow-up in this high-risk cohort;
however, it is interesting to note that the most frequent
cause of death was not due to cardiovascular causes butTable 6 Target vessel occlusion during follow-up.
Patient Vessel
occluded
Preoperative
stenosis
Stent
fracture
Secondary
procedure
1 Right renal artery Yes Yes No
2 Left renal artery No Yes No
3 Left renal artery No No Renal stentin
18 months af
initial proced
4 Left renal artery Yes Yes Norather due to carcinoma. No deaths occurred during follow-
up from aneurysm-related causes.
The early visceral vessel patency rate in the literature
ranges from 90.5% to 99.7%. Stenting of target vessels is
highly recommended to avoid early visceral vessel occlusion.
Stenting requires successful catheterisation of the target
vessel through fenestration. Inadequate device design and
target vessel ostial stenosis are predictors of per procedure
catheterisation failure and target vessel thrombosis. The
published 1-year target vessel patency rates range from
90.5% to 97% at 12 months.8 Renal artery occlusion rate
ranges from 2.3% to 4.3% in the literature. One case of
chronic mesenteric ischaemia relating to a superior mesen-
teric artery stenosis has been described. This patient was
successfully treated with a self-expanding stent.14 In our
study, we had no latemesenteric or coeliac artery occlusions
at follow-up and found four renal artery occlusions.
Deterioration in renal function (eGFR) ranged from 11%
to 25% (10% in our experience). Because the pathogenesis of
deterioration in renal function is multifactorial and is also
due to variations in reporting standards, assessment of the
impact of these grafts on renal function is difficult to
quantify. Nevertheless, renal impairment is statistically
more severe in open repair than in fenestrated EVAR.8
In the current series, 12 patients underwent endovas-
cular re-intervention for stent-related indications at
a median interval of 10 months representing a 9% re-
intervention rate. Six of these were for endoleaks and five
to protect threatened visceral branches. Angioplasty of an
anastamotic stenosis in an ileo-femoral bypass was also
carried out. These figures compare favourably with the
figure of 15% quoted in Nordon’s review of 351 cases from
various case series.8 There was a similar distribution of
indications for re-intervention in this review also, with 48%
for endoleaks and 52% for branch vessel issues.
Depending on the series, the rate of patients with
aneurysm diameter reduction ranges from 33% to 51% and
53% to 79% at 6 and 12 months, respectively. Similar results
have not been reported with standard EVAR endografts. The
proximal seal in a healthy and stable segment of the aorta
(compared with the infrarenal neck in standard EVAR) may
explain such findings.
To our knowledge, this current French multicentre study
is the largest cohort of fenestrated EVAR ever published.
The results of this study are concordant with previously
published literature. We wish to emphasise that this
current study has included every patient treated with
fenestrated devices during the study period, andTime from
surgery to
diagnosis
Preoperative
GFR
Post-occlusion
GFR
Haemodialysis
6 months 52 57 No
12 months 50 69 No
g
ter
ure
24 months 57 62 No
36 months 120 34 No
544 S. Amiot et al.consequently reflects a ‘nationwide’ learning curve.
Hence, we suggest that the current study demonstrates
fenestrated EVAR to be a technique whose role can be
expanded for use in centres where there is reasonable
endovascular experience and need not remain the preserve
of referral centres only.
In our experience, concordant with the literature, the
use of custom-made endografts with graft material incor-
porating the visceral arteries is safe and effective in pre-
venting aneurysm rupture in the medium term.
Competing interests
Ste´phan Haulon is a consultant for Cook Medical.
Funding
None
Acknowledgements
The following academic centres and physicians were
involved in this multicentre trial:
 Amiens: Prof. Reix
 Angers: Prof. Henon, Dr. Picquet, Prof. Lhoste
 Bordeaux: Prof. Ducasse, Prof. Midy
 Cre´teil: Prof. Becquemin, Prof. Desgranges,
Prof. Allaire, Prof. Kobeiter, Dr Cochennec
 Dijon: Prof. Steinmetz
 Lille: Prof. Haulon, Dr. Azzaoui, Dr. Koussa, Dr. Amiot
 Lyon: Prof. Chevalier, Prof. Feugier
 Marseille: Prof. Branchereau, Prof. Magnan, Prof.
Picquet, Prof. Bartoli
 Nantes: Prof. Patra, Dr. Goueffic
 Nice: Prof. Batt, Prof. Hassen-Khodja, Dr. Jean-Baptiste
 Paris: Prof. Julia, Prof. Sapoval
 Poitiers: Prof. Ricco, Dr. Marchand
 Reims: Prof. Cle´ment
 Rennes: Prof. Verhoye, Dr. Cardon, Dr. Heutot
 Saint Etienne: Prof. Favre, Prof. Albertini, Prof. Barral
 Tours: Prof. Lermusiaux, Dr. Martinez
References
1 Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van
Sambeek MR, Buskens E, et al. A randomized trial comparing
conventional and endovascular repair of abdominal aortic
aneurysms. N Engl J Med 2004;351(16):1607e18.
2 EVAR trial participants. Comparison of endovascular aneurysm
repair with open repair in patients with abdominal aortic
aneurysm (EVAR trial 1): 30-day operative mortality results:
randomised controlled trial. Lancet 2004;364(9437):843e8.
3 Boult M, Babidge W, Maddern G, Barnes M, Fitridge R, On Behalf
Of The Audit Reference Group. Predictors of success following
endovascular aneurysm repair: mid-term results. Eur J Vasc
Endovasc Surg 2006;31:123e9.
4 Greenberg RK, Haulon S, Lyden SP, Srivastava LP, Turc A,
Eagleton MJ, et al. Endovascular management of juxtarenalaneurysms with fenestrated endovascular grafting. J Vasc Surg
2004;39(2):279e86.
5 Crawford ES, Becket WC, Greer MS. Juxtarenal infrarenal
abdominal aortic aneurysm. Special diagnostic and therapeutic
considerations. Ann Surg 1986;203:661e70.
6 QvarfordtPG,StoneyRJ,Reilly LM,etal.Managementofpararenal
aneurysms of the abdominal aorta. J Vasc Surg 1986;3:84e93.
7 Taylor SM, Mills JL, Fujitani RM. The juxtarenal abdominal
aortic aneurysm. A more common problem than previously
realized? Arch Surg 1994;129:734e7.
8 Nordon IM, Loftus IM, Thomson MM. Modern treatment of jux-
tarenal abdominal aortic aneurysms with fenestrated endog-
rafting and open repair e a systematic review. Eur J Vasc
Endovasc Surg 2009;38:35e41.
9 Knott AW, Kalra M, Duncan AA, Reed NR, Bower TC, Hoskin TL,
et al. Open repair of juxtarenal aortic aneurysms (JRA) remains
a safe option in the era of fenestrated endografts. J Vasc Surg
2008;47(4):695e701.
10 Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Reporting standards for endovascular aortic
aneurysm repair. J Vasc Surg 2002;35(5):1048e60.
11 Crawford ES, DeNatale RW. Thoraco-abdominal aortic aneu-
rysm: observations regarding the natural course of the disease.
J Vasc Surg 1986;3(4):578e82.
12 Haulon S, Amiot S, Magnan PE, Becquemin JP, Lermusiaux P,
Koussa M, et al. An analysis of the French multicentre experi-
ence of fenestrated aortic endografts: medium-term outcomes.
Ann Surg; 27, in press.
13 Recommendations d’utilisation des endoprothe`ses aortiques
pour le traitement endovasculare des ane´vrismes de l’aorte
abdominale sous-re´nale, http://afssaps.sante.fr/index.htm;
De´cembre 2003.
14 Haddad F, Greenberg RK, Walker E, Nally J, O’Neill S, Kolin G,
et al. Fenestrated endovascular grafting: the renal side of the
story. J Vasc Surg 2005;41:181e90.
15 Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal
graft implantation for abdominal aortic aneurysm. Ann Vasc
Surg 1991;5:491e9.
16 Faruqi RM, Chuter TA, Reilly LM, Sawhney R, Wall S, Canto C,
et al. Endovascular repair of abdominal aortic aneurysm using
a pararenal fenestrated stent graft. J Endovasc Surg 1999;6:
354e8.
17 Kinney EV, Kaebnick HW, Mitchell RA, Jung MT. Repair of
mycotic paravisceral aneurysm with a fenestrated stent-graft.
J Endovasc Ther 2000;7(3):192e7.
18 Semmens JB, Lawrence-Brown MM, Hartley DE, Allen YB,
Green R, Nadkarni S. Outcomes of fenestrated endografts in the
treatment of abdominal aortic aneurysm in western Australia
(1997e2004). J Endovasc Ther 2006;13(3):320e9.
19 Verhoeven EL, Prins TR, Tielliu IF, van den Dungen JJ,
Zeebregts CJ, Hulsebos RG, et al. Treatment of short-necked
infrarenal aortic aneurysm with fenestrated stent-graft: short-
term results. Eur J Vasc Endovasc Surg 2004;27(5):447e83.
20 Muhs BE, Verhoeven EL, Zeebregts CJ, Tielliu IF, Prins TR,
Verhagen HJ, et al. Mid-term results of endovascular aneurysm
repair with branched and fenestrated endografts. J Vasc Surg
2006;44(1):9e15.
21 O’Neill S, Greenberg RK, Haddad F, Resch T, Sereika J, Katz E. A
prospective analysis of fenestrated endovascular grafting:
intermediate-term outcomes. Eur J Vasc Endovasc Surg 2006;
32(2):115e23.
22 Sun Z, Mwipatayi BP, Semmens JB, Lawrence-Browne MM.
Short to midterm outcomes of fenestrated endovascular
grafting: intermediate-term outcomes. J Endovasc Ther 2006
Dec;13(6):747e53.
